Dr. VanderWalde on Personalizing Therapy in Rectal Cancer

Video

Noam VanderWalde, MD, MS, discusses the push toward personalizing therapy in rectal cancer.

Noam VanderWalde, MD, MS, associate professor of radiation oncology, West Cancer Center and Research Institute, discusses the push toward personalizing therapy in rectal cancer.

Multiple standards of care are available for patients with rectal cancer, explains VanderWalde.

Historically, all patients with locally advanced rectal cancer received preoperative chemoradiation, VanderWalde says. In general, patients in the United States received long-course chemoradiation, whereas patients in Europe received short-course chemoradiation.

Following surgery, patients received chemotherapy as needed, VanderWalde adds.

The advent of total neoadjuvant therapy has expanded the armamentarium for patients in this space, says VanderWalde.

Treatment selection should be considered by a multidisciplinary team, including radiation oncologists, surgeons, and medical oncologists to optimize therapy for patients, VanderWalde concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,